Efficacy of liposome‐encapsulated 4‐n‐butylresorcinol and resveratrol cream in the treatment of melasma. (26th July 2019)

• Record Type: Journal Article
• Authors: Kwon, Soon‐Hyo; Yang, Ji Hoon; Shin, Jung‐Won; Park, Kyoung‐Chan; Huh, Chang‐Hun; Na, Jung‐Im
• Is Part Of: Journal of cosmetic dermatology. Volume 19:Number 4(2020)
• Page Start: 891
• Page End: 895
• Publication Date: 2019-07-26
• Subjects: 4‐n‐butylresorcinol -- melanin index -- melasma -- resveratrol; Skin -- Diseases -- Treatment -- Periodicals; Lasers in surgery -- Periodicals; Skin -- Pathophysiology -- Periodicals; Surgery, Plastic -- Periodicals; 616.5
• DOI: 10.1111/jocd.13080
• Languages: English
• ISSNs: 1473-2130

Abstract

Abstract: Backgrounds: We previously reported the efficacy of 0.1% 4‐n‐butylresorcinol (4nBR) cream in the treatment melasma and synergistic effect of 4nBR and resveratrol (RSV) to inhibit melanogenesis in vitro. Aims: To evaluate efficacy and safety of a cream which contains liposome‐encapsulated 4nBR and RSV in the treatment of melasma. Patients/Methods: A total of 21 female patients with melasma were treated with the cream for 4 weeks. At baseline, week 2, and week 4, melanin index (MI) of the lesional and preauricular nonlesional skin was measured and two blinded, independent dermatologists assessed the overall severity by 5‐point scale. Results: The lesional MI was significantly decreased at weeks 2 and 4 compared with the baseline while no significant change in the nonlesional MI was observed throughout the study. The mean investigator's global assessment score was also significantly improved at weeks 2 and 4. In patient's self‐assessment, 8 (38.1%) and 11 (52.3%) patients answered moderate to significant improvement in their melasma at weeks 2 and 4, respectively. No serious adverse events were reported. Conclusion: The cream containing liposome‐encapsulated 4nBR and RSV was shown to be effective and safe for the treatment of melasma with its effect appearing as early as 2 weeks.